Echo Therapeutics (ECTE) Posts Wider than Expected Q2 Loss of 8c/Share
Tweet
Share
E-mailGet Alerts ECTE Hot Sheet
Price: $0.00 --0%
Financial Fact:
Derivative warrant liability gain (loss): 3.68M
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
Derivative warrant liability gain (loss): 3.68M
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
Echo Therapeutics (NASDAQ: ECTE) reported Q2 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $30.9 thousand versus the consensus estimate of $190 thousand.
For earnings history and earnings-related data on Echo Therapeutics (ECTE) click here.
For earnings history and earnings-related data on Echo Therapeutics (ECTE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Etsy upgraded to buy at BofA on durable growth, buyback potential
- Deere shares climb as fiscal Q3 earnings and revenue top estimates
- Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
